Deciphera Pharmaceuticals, Inc. (DCPH) Social Stream



Deciphera Pharmaceuticals, Inc. (DCPH): $16.41

0.64 (+4.06%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add DCPH to Watchlist
Sign Up

Industry: Biotech


Ranked

of 401

in industry

Deciphera Pharmaceuticals Inc (DCPH) Price Targets From Analysts

Use the tables below to see what analysts covering Deciphera Pharmaceuticals Inc think about its future price and what recommendations they have for investors and traders.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-08 10 $64 $10 $23.8 $10.13 134.95%
2021-11-30 10 $64 $10 $19.1 $10.13 88.55%
2021-12-01 10 $64 $10 $20.5 $10.13 102.37%
2022-02-09 10 $64 $10 $17.4 $10.13 71.77%
2022-02-10 10 $64 $8 $17.2 $10.13 69.79%
2022-02-28 10 $64 $6 $16.7 $10.13 64.86%

The Trend in the Analyst Price Target


Over the past 22 months, DCPH's average price target has gone down $55.8.

Over the past 46 weeks, DCPH's average upside potential has been 109.43%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-04-10 5 84 70 75.73 43.81 72.86%
2021-07-24 11 84 60 71.78 33.28 115.69%
2021-08-28 11 84 44 68.50 30.51 124.52%
2021-09-19 11 84 44 68.50 32.98 107.7%
2021-12-01 10 64 10 18.10 8.00 126.25%

DCPH Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
2.4 4 0 5 1 1 10

The Trend in the Broker Recommendations


DCPH's average broker recommendation rating worsened by 1 over the prior 17 months.

The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.

  • In terms of how Deciphera Pharmaceuticals Inc fares relative to all US stocks, note that its variance in analysts' estimates is lower than -599.52% of that group.
  • Deciphera Pharmaceuticals Inc's average analyst price target is greater than 135.87% of stocks in the mid market cap category.
  • DCPH has a higher number of analysts covering the stock than 562.1% of Pharmaceutical Products stocks.
  • In the context of stocks in the mid market cap category, Deciphera Pharmaceuticals Inc's upside potential (average analyst target price relative to current price) is greater than 539.96% of them.

Stocks similar to Deciphera Pharmaceuticals Inc in the Pharmaceutical Products industry regarding analyst recommendations and price targets are CYTK, CYRX, and CORT.

Make investment decisions regarding DCPH using the data that counts. Try POWR Ratings for free.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6051 seconds.